• Category: Business
Alcon officially acquires Aerie
Business

Alcon officially acquires Aerie

Alcon announced Wednesday that it has completed its purchase of Aerie Pharmaceuticals, 3 months following the companies announcing their definite merger agreement.
Alcon to acquire STAAR Surgical
Business

Alcon to acquire STAAR Surgical

The $1.5 billion deal includes STAAR’s FDA-approved implantable collamer lenses; expected to close within 6 to 12 months.
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions
Business

Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions

Check out the latest leadership news from the eyecare space, including a new CEO at ViaLase and a leading optometrist joining myze.
Alcon to purchase LumiThera
Business

Alcon to purchase LumiThera

Targeting a Q3 sale, acquisition includes Valeda Light Delivery System, the first and only PBM treatment for early-to-intermediate dry AMD.
Alcon purchases majority stake in Aurion Biotech
Business

Alcon purchases majority stake in Aurion Biotech

Company replaces CEO and founder Greg Kunst, gaining access to groundbreaking CED cell therapy with plans for phase 3 clinical trials expected later this year.
Alcon to acquire Lensar and its next-gen FLACS portfolio
Business

Alcon to acquire Lensar and its next-gen FLACS portfolio

Deal includes the ALLY Robotic Cataract Laser System, the first FDA-cleared platform to enable femtosecond-laser-assisted cataract surgery.
Alcon innovator program identifies contact lens market needs
Business

Alcon innovator program identifies contact lens market needs

Inaugural initiative recruits ECPs to collect patient feedback and address top barriers influencing lens wear outcomes.
Alcon officially acquires BELKIN Vision
Business

Alcon officially acquires BELKIN Vision

Purchase involves the Israeli company’s FDA-cleared direct selective laser trabeculoplasty technology.
Alcon is buying Belkin Vision and its contact-less SLT glaucoma device
Business

Alcon is buying Belkin Vision and its contact-less SLT glaucoma device

Acquisition is estimated to be worth up to $335 million and will close in Q3 2024.